<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: β-blockers prevent <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> and reduced left ventricular ejection fraction, including <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that prevention of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> by the β-blocker/sympatholytic agent bucindolol is influenced by genetic variation in adrenergic receptors </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: From a substudy of the β-Blocker Evaluation of Survival Trial (n=1040), we identified those with the high functioning 389Arg versus the lower function 389Gly β(1) adrenergic receptor variant, and the loss of function α(2c)322-325 adrenergic receptor deletion versus the 322 to 325 <z:mp ids='MP_0002169'>wild-type</z:mp> (Wt)/deletion variant </plain></SENT>
<SENT sid="3" pm="."><plain>VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was recorded on case report forms as an adverse event </plain></SENT>
<SENT sid="4" pm="."><plain>There were 493 Arg 389 β(1) receptor homozygotes (β(1)389 Arg/Arg) versus 547 Gly389 carriers and 207 α(2c)322-325 deletion carriers versus 833 homozygous Wts (α(2c)322-325 Wt/Wt) </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> genotypes bucindolol was associated with a lower incidence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (subhazard ratio, 0.42 [0.27-0.64]; P=0.00006) </plain></SENT>
<SENT sid="6" pm="."><plain>Bucindolol reduced VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in β(1)389 Arg homozygotes (subhazard ratio, 0.26 [0.14-0.50]; P=0.00005) but not in β(1)389 Gly carriers (subhazard ratio, 0.60 [0.34-1.07]; P=0.09) </plain></SENT>
<SENT sid="7" pm="."><plain>For genotype combinations, the α(2c)322-325 polymorphism altered the VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> bucindolol response in β1389 Gly carriers, with α(2c) deletion genotypes associated with complete efficacy loss </plain></SENT>
<SENT sid="8" pm="."><plain>A test of interaction was statistically significant (P=0.028) for the treatment group and a β(1)389/α(2c)322-325 three genotype construct, effectively identifying patients who exhibited enhanced response, no substantial response modification and loss of response </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Bucindolol prevents VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in subjects with <z:hpo ids='HP_0001635'>heart failure</z:hpo> and reduced left ventricular ejection fractions, and this effect is modulated by β(1)389 Arg/Gly and α(2c)322-325 Wt/deletion adrenergic receptor polymorphisms </plain></SENT>
</text></document>